US.IDXX · Idexx Laboratories

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.235096730653869,
        "turnoverUsdM": 345.77100704000003,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.IDXX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 509.5942,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.6,
      "stop_loss_percent": 4.5,
      "take_profit_price": 570.5997,
      "target_multiplier": 2.2,
      "technical_strength": 2.13,
      "take_profit_percent": 7
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.5659277524763273,
    "stopLossPercent": 4.470193461307738,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 70.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 520.071,
    "ma50": 545.3664,
    "close": 533.44,
    "prevClose": 529.06,
    "avgVolume20": 508810,
    "volumeRatio": 1.27,
    "changePercent": 0.83
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.02289549376797706,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 1.2676816866150356,
      "ret_points": 4,
      "vol_points": 4,
      "range_ratio": 1.1086080303156451,
      "volat_points": 0,
      "day_range_pct": 0.027613302339531937,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 70.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 90,
        "contribution": 4.5
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 9.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 64,
        "contribution": 9.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 21.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72,
        "contribution": 21.6
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 61.7,
    "details": [
      "基本面分析總分: 4.5/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 9.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 21.6/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.5,
      "資金流": 12.4,
      "市場環境": 9.6,
      "情緒分析": 4,
      "技術信號": 21.6,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 345.77100704000003,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.IDXX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 722.9379963000001,
                "ma50": 714.3149974599999,
                "name": "QQQ",
                "close": 737.92999,
                "points": 2
              },
              "spy": {
                "ma20": 765.0209984,
                "ma50": 762.4543978399996,
                "name": "SPY",
                "close": 764.20001,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.235096730653869,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.8
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142358084,
                "url": "https://finnhub.io/api/news?id=05e3ae99c02c75d37191e4166298b8610ba2bcc2b374dfe2cfde6df8b5e8add7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.",
                "category": "company",
                "datetime": 1790167980,
                "headline": "Should You Continue to Hold IDXX Stock in Your Portfolio?"
              },
              {
                "id": 142275018,
                "url": "https://finnhub.io/api/news?id=5cb6e4043fcded5e9449e09b4d31007b69024b49e7d66f4d9dcfed50e8639743",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the […]",
                "category": "company",
                "datetime": 1789849050,
                "headline": "IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics"
              },
              {
                "id": 142239522,
                "url": "https://finnhub.io/api/news?id=5ff858665882f2b9e0419c93ddbd697b0780e279cf40b2830df3c311d21870d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...",
                "category": "company",
                "datetime": 1789701323,
                "headline": "IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide"
              },
              {
                "id": 142233039,
                "url": "https://finnhub.io/api/news?id=c7ec317f824a0a46cc75890e51b0b45bffa5a5f25c5fdd8be0f530ccd3fb9829",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (IDXX) drew fresh attention after expanding its Faecal Dx antigen testing platform in the United Kingdom to cover taeniid tapeworms, including Taenia and Echinococcus species, during routine veterinary visits. Recent moves by IDEXX Laboratories, including the Faecal Dx expansion and the CoVetAI acquisition, come as the share price sits at US$506.48. The year-to-date share price return is down 24.4%, but the 3-year total shareholder return remains positive at 15.46%,...",
                "category": "company",
                "datetime": 1789683361,
                "headline": "IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus"
              },
              {
                "id": 142223596,
                "url": "https://finnhub.io/api/news?id=475c2b8ee783d2e4f92e919222c9c1a0697985d5e5076d4ea97729705d462408",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...",
                "category": "company",
                "datetime": 1789643501,
                "headline": "Is IDEXX’s Expanded Zoonosis Testing Menu Altering The Investment Case For IDEXX Laboratories (IDXX)?"
              },
              {
                "id": 142138882,
                "url": "https://finnhub.io/api/news?id=f7e365942b5fa35462d62c50fd7f29a920647bee2cdf6fa8e95a8f8a4b659940",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "IDEXX Laboratories, Inc. (IDXX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsMichael Erickson...",
                "category": "company",
                "datetime": 1789390912,
                "headline": "IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142374718,
                "url": "https://finnhub.io/api/news?id=bc9b0f8635277ab701dcc3c163514dd4b9d9aa67b7a84b17824541920a541163",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "The companion animal diagnostics market is projected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, registering an 8.7% CAGR. Growth is driven by rising pet healthcare spending, preventive care, chronic and infectious diseases, and advances in AI, molecular diagnostics, point-of-care testing and automated analyzers. Molecular diagnostics will record the fastest growth, while consumables remain the leading product segment. Asia Pacific is expected to be the fastest-growing reg",
                "category": "company",
                "datetime": 1790245140,
                "headline": "Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & Zoetis"
              },
              {
                "id": 142358084,
                "url": "https://finnhub.io/api/news?id=05e3ae99c02c75d37191e4166298b8610ba2bcc2b374dfe2cfde6df8b5e8add7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.",
                "category": "company",
                "datetime": 1790167980,
                "headline": "Should You Continue to Hold IDXX Stock in Your Portfolio?"
              },
              {
                "id": 142289020,
                "url": "https://finnhub.io/api/news?id=e5ecdbcd71df01aa545692f9f346f9e230dc1f1afa7d81c126ff6d3f024d6ceb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure",
                "category": "company",
                "datetime": 1789916527,
                "headline": "IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets"
              },
              {
                "id": 142289021,
                "url": "https://finnhub.io/api/news?id=31197699c0aca87f620df2033d75551cb7479e6cc7734c2f82b175537b6cd6b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of",
                "category": "company",
                "datetime": 1789912922,
                "headline": "IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference"
              },
              {
                "id": 142275018,
                "url": "https://finnhub.io/api/news?id=5cb6e4043fcded5e9449e09b4d31007b69024b49e7d66f4d9dcfed50e8639743",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the […]",
                "category": "company",
                "datetime": 1789849050,
                "headline": "IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics"
              },
              {
                "id": 142239522,
                "url": "https://finnhub.io/api/news?id=5ff858665882f2b9e0419c93ddbd697b0780e279cf40b2830df3c311d21870d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...",
                "category": "company",
                "datetime": 1789701323,
                "headline": "IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide"
              },
              {
                "id": 142233039,
                "url": "https://finnhub.io/api/news?id=c7ec317f824a0a46cc75890e51b0b45bffa5a5f25c5fdd8be0f530ccd3fb9829",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (IDXX) drew fresh attention after expanding its Faecal Dx antigen testing platform in the United Kingdom to cover taeniid tapeworms, including Taenia and Echinococcus species, during routine veterinary visits. Recent moves by IDEXX Laboratories, including the Faecal Dx expansion and the CoVetAI acquisition, come as the share price sits at US$506.48. The year-to-date share price return is down 24.4%, but the 3-year total shareholder return remains positive at 15.46%,...",
                "category": "company",
                "datetime": 1789683361,
                "headline": "IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus"
              },
              {
                "id": 142231842,
                "url": "https://finnhub.io/api/news?id=b6d38631685a59d322eca301d3fce11837594300180b965f9ecbf212974508c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.",
                "category": "company",
                "datetime": 1789650480,
                "headline": "IDEXX Stock Gains Following the Acquisition of CoVet"
              },
              {
                "id": 142223596,
                "url": "https://finnhub.io/api/news?id=475c2b8ee783d2e4f92e919222c9c1a0697985d5e5076d4ea97729705d462408",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...",
                "category": "company",
                "datetime": 1789643501,
                "headline": "Is IDEXX’s Expanded Zoonosis Testing Menu Altering The Investment Case For IDEXX Laboratories (IDXX)?"
              },
              {
                "id": 142212624,
                "url": "https://finnhub.io/api/news?id=af9d4531a94a5fe3d79fadfa942ff4f94b1d170df601af6cb13a6b894a03ec6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "WESTBROOK, Maine, September 17, 2026--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.",
                "category": "company",
                "datetime": 1789628400,
                "headline": "IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection"
              },
              {
                "id": 142194230,
                "url": "https://finnhub.io/api/news?id=2cc2687f9f9e666cf9028601b73310dccb000aa161d23eebe5b2ac84009b4bed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "WESTBROOK, Maine, September 16, 2026--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.",
                "category": "company",
                "datetime": 1789556400,
                "headline": "IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence"
              },
              {
                "id": 142138882,
                "url": "https://finnhub.io/api/news?id=f7e365942b5fa35462d62c50fd7f29a920647bee2cdf6fa8e95a8f8a4b659940",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "IDEXX Laboratories, Inc. (IDXX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsMichael Erickson...",
                "category": "company",
                "datetime": 1789390912,
                "headline": "IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142125444,
                "url": "https://finnhub.io/api/news?id=a4035f7d169de499a6bf760b4a6f3eee978a9e675074b8e12637111d8b78fc0a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1056792912/image_1056792912.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "Ron Baron’s BAMCO 13F hits $66.6B, led by SpaceX, Tesla & MSCI.",
                "category": "company",
                "datetime": 1789317731,
                "headline": "Tracking Ron Baron's BAMCO Portfolio - Q2 2026 Update"
              },
              {
                "id": 142063291,
                "url": "https://finnhub.io/api/news?id=45a4c767641875677341490c5c57df95988778e7db0af9183d8a84bc58b8398b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.",
                "category": "company",
                "datetime": 1789059954,
                "headline": "Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?"
              },
              {
                "id": 142060161,
                "url": "https://finnhub.io/api/news?id=57e39d64a6d8b3ccef6bec1c6dd61092ebd9edef3f36bd0690b13626d83d3d1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.",
                "category": "company",
                "datetime": 1789039201,
                "headline": "Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock"
              },
              {
                "id": 142086761,
                "url": "https://finnhub.io/api/news?id=c09628bcf5f21f4776a3b3675749871ba5c376e376db4a730357955e1ab55212",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "In a new SEC filing on September 9, it was revealed that Kingsley, Board Member at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options.\nWhat Happened: Disclosed in a Form 4 filing",
                "category": "company",
                "datetime": 1789038085,
                "headline": "Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories"
              },
              {
                "id": 142061148,
                "url": "https://finnhub.io/api/news?id=7f0de51f256b61b9df0e35d286863ba8fe033eb1dbec973436a99a804309379f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351963587/image_1351963587.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "Top contributors include Space Exploration Technologies, Tesla, Red Rock Resorts, Hyatt Hotels and Birkenstock Holding. Read more here.",
                "category": "company",
                "datetime": 1789035300,
                "headline": "Baron Partners Fund Q2 2026 Contributors And Detractors"
              },
              {
                "id": 142062118,
                "url": "https://finnhub.io/api/news?id=1d4950ac362cdb63b062bee890fd5d2a425808e745bafddbf3ac1c4a50640db9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Despite trailing the Dow over the past year, IDEXX still has Wall Street on its side, with analysts maintaining a cautiously optimistic view on its future prospects.",
                "category": "company",
                "datetime": 1789032067,
                "headline": "Is IDEXX Laboratories Stock Underperforming the Dow?"
              },
              {
                "id": 141399397,
                "url": "https://finnhub.io/api/news?id=e9276ab12e47a0d3dd90df920e651f06fcf504acce7c2175389d383dc3c70589",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972334358/image_1972334358.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "The Fund's weightings are significantly different than those of the Benchmark, which explains why the Fund has such high active share of almost 100%. Read more here.",
                "category": "company",
                "datetime": 1788429000,
                "headline": "Baron Focused Growth Fund Q2 2026 Portfolio Update"
              },
              {
                "id": 141361360,
                "url": "https://finnhub.io/api/news?id=b3dce0b1c9a4c4655954dc9ce268a2fa6b35340cb08c89f935eac9e3aa25c5c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).",
                "category": "company",
                "datetime": 1788202800,
                "headline": "IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141350993,
                "url": "https://finnhub.io/api/news?id=891189d904c37cd1a42d9adf35703a2729dacbb6529f24d5bb557f9ddb970015",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/538053368/image_538053368.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "Fundsmith's 13F portfolio rose to ~$13.65B in Q2 2026, expanding holdings from 34 to 41. Click here to read more about the portfolio.",
                "category": "company",
                "datetime": 1788120600,
                "headline": "Tracking Terry Smith's Fundsmith 13F Portfolio - Q2 2026 Update"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 6,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.8,
            "source_article_count": 21,
            "discarded_article_count": 15
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(14.1%→5.3%)；靠近20日高位；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 496383.3333333333,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 496880,
              "avg_vol_20": 511320,
              "avg_vol_30": 496383.3333333333,
              "range_pct_10": 0.05280820710857837,
              "range_pct_20": 0.11365851829634081,
              "range_pct_30": 0.14050316811637664,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0010005707954202,
              "dist_to_20d_high": 0.049533159602543606,
              "down_shrink_days": 2,
              "breakout_level_20d": 561.23999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.37585065032012754
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.235096730653869,
              "turnoverUsdM": 345.77100704000003,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.IDXX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 509.5942,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.6,
            "stop_loss_percent": 4.5,
            "take_profit_price": 570.5997,
            "target_multiplier": 2.2,
            "technical_strength": 2.13,
            "take_profit_percent": 7
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.5659277524763273,
          "stopLossPercent": 4.470193461307738,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.IDXX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 11.9229,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.24
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 73.25
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0399
    },
    "kdj": {
      "d": 69.56,
      "j": 105.29,
      "k": 81.47,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 63.4
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 4893291,
      "recentSlope": 306109.1,
      "previousSlope": -139740
    },
    "rsi": 62.93,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 504.9157,
      "position": "SAR喺價下",
      "distancePct": 5.35,
      "previousTrend": "上升"
    },
    "ma50": 545.3664,
    "macd": {
      "macd": -6.299858532949543,
      "trend": "看漲",
      "signal": -9.77540128596211,
      "histogram": 3.475542753012567
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 520.5481,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.27,
      "score": 6,
      "avgVolume": 508810,
      "currentVolume": 648191
    },
    "derived": {
      "ma20": 520.071,
      "ma50": 545.3664,
      "prevClose": 529.06,
      "avgVolume10": 501339,
      "avgVolume20": 508810,
      "changePercent": 0.83,
      "avgVolumeForScore": 508810
    },
    "ma_cross": {
      "ma20": 520.071,
      "ma50": 545.3664,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 521.2335,
      "prevMa50": 545.9738,
      "spreadPct": 4.64,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 497.3597,
      "upper": 542.7823,
      "position": "上半部"
    },
    "rsi_short": 75.62,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.27
    }
  }
}

{
  "close": 533.44,
  "volume": 648191,
  "changePercent": 0.83
}